

### PRIOR AUTHORIZATION REQUEST FORM

#### **EOC ID:**

# Sprycel

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. **Please note any information left blank or illegible may delay the review process.** 

Patient Name:	Prescriber Name:	Prescriber Name: Supervising Physician:	
	Supervising Physician	i.	
Member/Subscriber Number:	Fax:	Phone:	
Date of Birth:	Office Contact:		
Group Number:	NPI:	State Lic ID:	
Address:	Address:		
City, State ZIP:	City, State ZIP:		
Primary Phone:	Specialty/facility name (	if applicable):	
Drug Name and Strength:			
Directions / SIG:			
Please attach any pertinent medical history or info	rmation for this patient that ma ving questions and sign.	y support approval. Please answer the	
Q1. Please provide ICD code(s) for diagnosis			
Q2. What diagnosis is this drug being prescribed for	 r?		
☐ Philadelphia chromosome positive (Ph+) Acute		)	
☐ Philadelphia chromosome positive (Ph+) Chroni	• •	-,	
☐ Other	o myolola Loanomia (omz)		
Q3. If you selected "other" in question 2, please pro higher recommendation per NCCN compendia or gu		s consistent with a category 1 or	
Q4. Is the prescribing physician an Oncologist or He	ematologist?		
☐ Yes ☐ No			
Q5. If ALL, was the patient resistant or intolerant of	prior therapy?		
☐ Yes ☐ No			
Q6. If CML, indicate the phase the disease is in			
☐ Chronic phase ☐ Accelerated phase	e Myeloid blast pha	ase	



#### PRIOR AUTHORIZATION REQUEST FORM

#### **EOC ID:**

## Sprycel

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. **Please note any information left blank or illegible may delay the review process.** 

Patient Name:		Prescriber Name: Supervising Physician:
Q7. If chronic phase	e CML, is the patient newly	iagnosed?
Yes	☐ No	
	lerated, myeloid or lymphoid erapy including imatinib?	blast phase CML and not newly diagnosed, is the patient resistant or
☐ Yes	☐ No	
Q9. Additional Com	ments	
	Prescriber Signature	Date
	,	gning above, I certify that applying the standard review timeframe may
seriously jeopardize t	he life or health of the enrol	ee or the enrollee's ability to regain maximum function
		nedical necessity denial. Requesting providers may speak to a SWHP pharmac se to have an opportunity to help impact the decision on a request before cover

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document